Compare BARK & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | CMPS |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United Kingdom |
| Employees | 501 | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 1.9B |
| IPO Year | 2020 | 2020 |
| Metric | BARK | CMPS |
|---|---|---|
| Price | $8.30 | $13.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $37.50 | $25.38 |
| AVG Volume (30 Days) | 45.4K | ★ 2.5M |
| Earning Date | 06-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $394,843,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | $101.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $4.88 |
| 52 Week High | $11.32 | $15.87 |
| Indicator | BARK | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 37.33 | 43.29 |
| Support Level | $0.59 | $12.95 |
| Resistance Level | $9.98 | $14.87 |
| Average True Range (ATR) | 0.56 | 0.92 |
| MACD | -0.14 | -0.16 |
| Stochastic Oscillator | 11.95 | 6.68 |
BARK Inc believe that dogs and humans are good together and it aspire to be the world's favorite dog brand. It is a team of dog-obsessed people committed to delivering personalization at scale by satisfying each dog's distinct personality, preferences, and needs with the products and services. It is an omnichannel brand that designs and develops proprietary products for dogs across two key brands: BarkBox and Super Chewer. All of its products are designed and developed in-house, and are BARK branded. Its segments are DTC, and Commerce. It generates majority of revenue from DTC. Direct to Consumer generates revenue from subscription products that feature monthly themes of premium quality BarkBox and Super Chewer toys and BARK-branded treats and chews.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.